The Spanish Competition Authority closes abuse of dominance proceedings through a commitments decision against a pharmaceutical company (IMS Health)

Callol, Pedro

Previous article The Indian Competition Authority opens its third investigation in a short amount of time into the abuse of dominance by one of the largest national energy companies (Mohan Meakin / Gail India) Next article The Paris Court of Appeal denies a utility company’s request for information regarding rival’s settlement with the French Competition Authority (ENGIE / Direct Energie)

13 Jul 2017

The Spanish Competition Authority closes abuse of dominance proceedings through a commitments decision against a pharmaceutical company (IMS Health)

KEYWORDS

Reference

Spanish Competition Authority, IMS Health, file S/DC/0567/15, 13 July 2017 (Spanish)

On 13 July 2017, the NMCC closed the Article 102 TFEU and Article 2 of the Spanish Competition Act (Competition Act) proceedings related to the supply of pharmaceutical marketing data to IMS Health (IMS) by means of a commitments decision. The NMCC initiated the investigation, as a result of the complaint lodged by Health market Research España (HmR) against IMS for abuse of dominant position by establishing a network of data supply agreements

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Author

Pedro Callol
Callol, Coca & Asociados (Madrid)

Spain 169 contributions 45124 visits

Quotation

Pedro Callol, The Spanish Competition Authority closes abuse of dominance proceedings through a commitments decision against a pharmaceutical company (IMS Health), 13 July 2017, e-Competitions July 2017, Art. N° 85250

Visites 373